Welcome to the e-CCO Library!

P692: Positive histological margins is a risk factor of recurrence after ileocaecal resection in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Riault*1, M. Diouf2, D. Chatelain2, J. p. Le Mouel1, J. Loreau1, J. Turpin1, C. Yzet1, F. Brazier1, C. Sabbagh2, J. l. Dupas1, E. Nguyen-Khac1, M. Fumery1

Created: Friday, 22 February 2019, 9:41 AM
P693 Development and evaluation of i-TRACKER infliximab and i-TRACKER anti-Infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Noguier1, C. Montaillier1, S. Daviere2, L. Colombeau1, E. Parussini1

Created: Thursday, 30 January 2020, 10:12 AM
P693: Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of Inflammatory Bowel Disease- An IG-IBD study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Pugliese, D.(1);Privitera, G.(2)*;Armuzzi, A.(3);
Created: Friday, 14 July 2023, 11:12 AM
P693: Patients with inflammatory bowel disease who are on immunosuppressive therapy perform regular gynecologic screening for uterine cervical cancer?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vázquez-Morόn J.M., Cabello Fernández A., Pallarés-Manrique H., Ramos-Lora M.

Created: Wednesday, 20 February 2019, 10:36 AM
P693: Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Walsh1, A. Kormilitzin2, C. Hinds3, V. Sexton4, J. Wilson1, O. Brain1*, S. Keshav1, H. Uhlig1, J. Geddes4, G. Goodwin4, M. Peters5, G. Collins6, S. Travis1

Created: Thursday, 21 February 2019, 9:14 AM
P693: Vedolizumab treatment for pouch inflammation
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Hirsch*1, H. Tulchinsky2, N. Maharshak1

Created: Friday, 22 February 2019, 9:41 AM
P693: Willingness and hesitancy to the telemedicine in patients with inflammatory bowel disease during COVID-19 outbreak. Preliminary results of a survey in an Italian IBD Center
Year: 2022
Source: ECCO'22
Authors: Bossa, F.(1);Guerra, M.(1);Carparelli, S.(1);Antonella, M.(1);Terracciano, F.(1);Costantino, A.(2);Caprioli, F.(2);Valvano, M.R.(1);Martino, G.(1);Nardella, M.(1);Perri, F.(1);
Created: Friday, 11 February 2022, 3:56 PM
P694 Validation of two commercial assays for therapeutic drug monitoring of adalimumab biosimilars
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Berghmans1, J. Naudts2, B. Ferkinghoff3, H. Gören3, M.L. Henke3, A. Lennerz4, T. Van Stappen4

Created: Thursday, 30 January 2020, 10:12 AM
P694: COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy.
Year: 2022
Source: ECCO'22
Authors: Ramos Lopez, L.(1);Carrillo-Palau, M.(1);Alonso-Abreu , I.(1);Reygosa, C.(1);Hernández-Buylla, N.(1);Amaral , C.(1);Hernández, A.(1);Benítez-Zafra, F.(1);Pérez-González, F.(1);Quintana-Díaz, H.(1);Hernández-Guerra, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P694: Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Burisch J.*1, Halfvarson J.2, Kupcinskas L.3, Hernandez V.4, Kaimakliotis I.5, Valpiani D.6, Pedersen N.7, Duricova D.8, Kievit L.9, Dahlerup J.F.10, Fumery M.11, Salupere R.12, Arebi N.13, Nielsen K.R.14, Giannotta M.15, Oksanen P.16, Katsanos K.H.17, Vegh Z.18, Ellul P.19, Schwartz D.20, Čuković-Čavka S.21, D'Incà R.22, Turcan S.23, Magro F.24,25,26, Goldis A.27, Langholz E.28, Lakatos P.L.18, Munkholm P.1 EpiCom Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P694: Genetic predisposition and thiopurine-induced pancreatitis in inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Burnet*1, N. de Suray2, B. De Vroey3, P. Hoang4, J-C. Coche5, M. Denis1, J-L. Gala6, O. Dewit1

Created: Friday, 22 February 2019, 9:41 AM
P694: Long-term monitoring of post-surgical recurrence in Crohn's disease using a strategy based on the periodic determination of fecal calprotectin in patients without early postoperative recurrence
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mañosa CiriaPhD, M.(1,2)*;Oller, B.(1);Garcia-Planella, E.(3);Guardiola, J.(4);Cañete, F.(1,2);Gonzalez Muñoza, C.(3);Camps, B.(4);Calafat, M.(1,2);Domènech, E.(2,5);
Created: Friday, 14 July 2023, 11:12 AM
P694: Non-medical mandatory reversed and back and forth switch between infliximab and its biosimilar: Early clinical outcomes
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Ilias1*, K. Szanto2, L. Gonczi1, Z. Kurti1, P.A. Golovics3, E. Schafer3, K. Farkas2, T. Szamosi3, Z. Szepes2, T. Molnar2, A. Vincze4, P.L. Lakatos1,5

Created: Thursday, 21 February 2019, 9:14 AM
P695 Vedolizumab induction and maintenance though levels and long-term clinical and biochemical status in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Gutiérrez Casbas1, L. Sempere Robles2, R. Muñoz Pérez2, A. Rodríguez Angulo2, S. Climent3, J.I. Cameo Lorenzo2, M. Díaz3, P. Boada3, P. Más-Serrano3

Created: Thursday, 30 January 2020, 10:12 AM
P695: Attitudes and predictors of COVID-19 vaccine uptake in patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Zhang, E.(1);Gupta, A.(1);Macrae, F.A.(1);Christensen, B.(1);
Created: Friday, 11 February 2022, 3:56 PM
P695: Does anticoagulation treatment increase the rate of major bleeding complications in patients with IBD and venous thromboembolism?
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Novacek1*, S. Tonko1, A. Sobala1, H. Tilg2, W. Petritsch3, W. Reinisch1, A. Mayer4, T. Haas5, O. Ludwiczek6, T. Feichtenschlager7, H. Fuchssteiner8, P. Steiner9, H. Vogelsang1, W. Miehsler10, R. Platzer11, W. Tillinger12, A. Schmid13, B. Blaha14, H. Herkner15

Created: Thursday, 21 February 2019, 9:14 AM
P695: Effectiveness and Safety of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: McShane, C.(1)*;Varley, R.(2);Fennessy, A.(3);Campion, J.(4);Ring, E.(5);Kelly, O.(5);Slattery, E.(4);Doherty, G.(6);McCarthy, J.(2);Kevans, D.(7);
Created: Friday, 14 July 2023, 11:12 AM
P695: Feasibility and safety of strictureplasties performed by laparoscopic approach for complicated Crohn’s disease: A prospective observational cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. M. Sampietro1, F. Colombo*1, A. Frontali2, C. Baldi1, L. Conti1, D. Dilillo3, P. Fiorina4, G. Maconi5, S. Ardizzone5, F. Corsi6, G. Zuccotti3, D. Foschi1

Created: Friday, 22 February 2019, 9:41 AM
P695: The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Burisch J.*1, Halfvarson J.2, Kupcinskas L.3, Hernandez V.4, Kaimakliotis I.5, Valpiani D.6, Pedersen N.7, Duricova D.8, Kievit L.9, Dahlerup J.F.10, Fumery M.11, Salupere R.12, Arebi N.13, Nielsen K.R.14, Giannotta M.15, Oksanen P.16, Katsanos K.H.17, Vegh Z.18, Ellul P.19, Schwartz D.20, Čuković-Čavka S.21, D'Incà R.22, Turcan S.23, Magro F.24,25,26, Goldis A.27, Langholz E.28, Lakatos P.L.18, Munkholm P.1 EpiCom Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P696 The usefulness to treatment enhancement for the patients of ulcerative colitis with clinical remission diagnosed as Mayo endoscopic subscore 1
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Kubota Kajiwara, K. Uchiyama, Y. Azuma, R. Yasuda, S. Takayama, T. Takagi, Y. Naitoh

Created: Thursday, 30 January 2020, 10:12 AM